Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine for cognitive side-effects of tamoxifen in postmenopausal women with ER+ breast cancer
2016-000506-11Phase 2Active
- Sponsor
- Limoxifen
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guanfacine in breast cancer and Iatrogenic cognitive impairment (2 arms), sponsored by Limoxifen. Primary endpoint: Primary cognitive function endpoint. Started Jun 2016; status: active.
02
Drugs
guanfacine
03
Conditions
breast cancerIatrogenic cognitive impairment
Beyond the preview
Go deeper on 2016-000506-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000506-11.